Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- For the main intervention part of the trial, people aged 20 years or older may be eligible. For the assessments taken at the start and end of the study, people aged 30 years or older may be eligible.
- People who live in the specific selected areas of Kabul, Afghanistan that have been chosen for this study.
- People who are willing to take part and agree to give their consent to participate.
- People with normal blood sugar levels, slightly raised blood sugar levels, or diagnosed diabetes are welcome to take part.
- People who are able to attend the scheduled meetings and activities as outlined in the study plan.
Who may not be able to join:
- For the main intervention part, people under the age of 20 are not eligible. For the start and end assessments, people under the age of 30 are not eligible.
- People who are not willing to give their consent to participate.
- People who have health conditions that may prevent them from fully taking part in the study activities (confirm with trial site).
- People who are unlikely to follow the study rules and procedures as required.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Abdul Rahman Shahab, MPH, Deputy Country Director, HealthNet TPO, Afghanistan
Phone: +93786611325
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To culturally adapt PLA-based intervention (D-Magic) for primary prevention and control of TIIDM in rural communities of Afghanistan; To test the feasibility of the culturally adapted PLA-based intervention (D-Magic); To test the acceptability of the culturally adapted PLA-based intervention (D-Magic)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.